Literature DB >> 26735404

Targeting a regulator of protein homeostasis in myeloproliferative neoplasms.

Lindsay M LaFave1, Ross L Levine2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26735404     DOI: 10.1038/nm.4028

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

Review 1.  Targeting endoplasmic reticulum stress in insulin resistance.

Authors:  Laia Salvadó; Xavier Palomer; Emma Barroso; Manuel Vázquez-Carrera
Journal:  Trends Endocrinol Metab       Date:  2015-06-12       Impact factor: 12.015

2.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

3.  Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling.

Authors:  Fernando G Osorio; Clara Soria-Valles; Olaya Santiago-Fernández; Teresa Bernal; María Mittelbrunn; Enrique Colado; Francisco Rodríguez; Elena Bonzon-Kulichenko; Jesús Vázquez; Montserrat Porta-de-la-Riva; Julián Cerón; Antonio Fueyo; Juan Li; Anthony R Green; José M P Freije; Carlos López-Otín
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

4.  Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

Authors:  Priya Koppikar; Omar Abdel-Wahab; Cyrus Hedvat; Sachie Marubayashi; Jay Patel; Aviva Goel; Nicole Kucine; Jeffrey R Gardner; Andrew P Combs; Kris Vaddi; Patrick J Haley; Timothy C Burn; Mark Rupar; Jacqueline F Bromberg; Mark L Heaney; Elisa de Stanchina; Jordan S Fridman; Ross L Levine
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

5.  JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Authors:  Maria Kleppe; Minsuk Kwak; Priya Koppikar; Markus Riester; Matthew Keller; Lennart Bastian; Todd Hricik; Neha Bhagwat; Anna Sophia McKenney; Efthymia Papalexi; Omar Abdel-Wahab; Raajit Rampal; Sachie Marubayashi; Jonathan J Chen; Vincent Romanet; Jordan S Fridman; Jacqueline Bromberg; Julie Teruya-Feldstein; Masato Murakami; Thomas Radimerski; Franziska Michor; Rong Fan; Ross L Levine
Journal:  Cancer Discov       Date:  2015-01-08       Impact factor: 39.397

6.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

7.  The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.

Authors:  Michael Deininger; Jerald Radich; Timothy C Burn; Reid Huber; Dilan Paranagama; Srdan Verstovsek
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

Review 8.  Insulin and insulin-like growth factor signalling in neoplasia.

Authors:  Michael Pollak
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

9.  Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer.

Authors:  Axel Muendlein; Alois H Lang; Simone Geller-Rhomberg; Thomas Winder; Klaus Gasser; Heinz Drexel; Thomas Decker; Elisabeth Mueller-Holzner; Martina Chamson; Christian Marth; Michael Hubalek
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-23       Impact factor: 4.553

10.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

View more
  2 in total

1.  The novel tumor suppressor AIRAPL regulates IGF1R proteostasis.

Authors:  Fernando G Osorio; José M P Freije; Carlos López-Otín
Journal:  Cell Cycle       Date:  2016-02-22       Impact factor: 4.534

2.  Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms.

Authors:  Zhu Shen; Wenfei Du; Cecelia Perkins; Lenn Fechter; Vanita Natu; Holden Maecker; Jesse Rowley; Jason Gotlib; James Zehnder; Anandi Krishnan
Journal:  Cell Rep Med       Date:  2021-10-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.